UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for brain cancer and glioblastoma in the United Kingdom. Explore treatment pathways including surgery, radiation, and novel therapies.
Brain tumours affect ~12,000 people per year in the UK. Glioblastoma (GBM) is the most aggressive type, with ~2,500 new cases yearly. Despite being relatively rare, brain tumours are the biggest cancer killer of children and adults under 40. The Brain Tumour Charity and NHS are investing heavily in research to improve outcomes.
Key biomarkers: IDH mutation (isocitrate dehydrogenase - mutant tumours have better prognosis, ~70% of grade II-III gliomas), MGMT methylation (predicts response to temozolomide chemotherapy), 1p/19q co-deletion (oligodendroglioma, responds well to PCV chemotherapy), and EGFR amplification. These guide both treatment and prognosis.
Standard treatment for GBM: maximal safe surgery, followed by radiotherapy + temozolomide (Stupp protocol), then adjuvant temozolomide. Tumour-treating fields (Optune) can be added and are approved by NICE. For recurrent disease, options include re-surgery, lomustine, and clinical trials. IDH-mutant lower-grade gliomas may use surgery ± radiotherapy ± PCV chemotherapy.
Active UK brain tumour trials include: immunotherapy (vaccines, checkpoint inhibitors, CAR-T), oncolytic viruses, new targeted agents, focused ultrasound for drug delivery across the blood-brain barrier, and adaptive radiotherapy. The Tessa Jowell BRAIN MATRIX is a major UK initiative connecting patients to molecularly-guided trials.
28 recruiting trials — 1 early-stage, 6 recurrent or metastatic, 21 stage not specified
Free AI-powered matching - no signup required
Search glioblastoma Trials →